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The main change that has occurred in the GLOB blood group 
system since the GLOB review published in this journal in 2013 
is the addition of an antigen. The high-prevalence PX2 antigen, 
originally recognized as the x2 glycosphingolipid, is expressed 
on red blood cells of most individuals and is elevated in the rare 
PP1Pk-negative p blood group phenotype. P synthase, encoded by 
B3GALNT1, was found to elongate paragloboside to PX2 by adding 
the terminal β3GalNAc moiety. Hence, PX2 was moved from the 
GLOB collection to the GLOB system. The presence of naturally-
occurring anti-PX2 was noted in P1k and P2k individuals exhibiting 
nonfunctional P synthase. Although the clinical significance 
of this specificity remains unclear, a recommendation to avoid 
transfusing Pk patients with p phenotype blood has been made. 
Currently, 13 mutations at the highly conserved B3GALNT1 locus 
have been found to abolish P synthase function and are recognized 
as null alleles by the International Society of Blood Transfusion. 
A new allele with a missense mutation but resulting in normal 
expression of P has been assigned GLOB*02. Finally, the GLOB 
collection was made obsolete after the move of LKE antigen to the 
901 series. Immunohematology 2018;34:161–163.
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In a series of experiments, P synthase encoded by 
B3GALNT1 was shown to synthesize the PX2 antigen by 
the addition of GalNAc in β1,3-linkage to the paragloboside 
precursor (Fig. 1). The presence of naturally occurring anti-
PX2 in all tested individuals with the rare Pk phenotype was 
also noted.1 Consequently, PX2 was reclassified and moved 
from the GLOB collection (International Society of Blood 
Transfusion [ISBT] no. 209), to which it was added as late as 
2016, to the GLOB blood group system (ISBT no. 028) and 
accepted as the second blood group antigen (GLOB2) after P 
(GLOB1).2 This change, however, gave rise to some confusion, 
because Pk, now belonging to the P1PK blood group system 
(ISBT no. 003), was previously identified as 209.002 (i.e., 
the second antigen of the GLOB collection). In an attempt to 
shed light on the already complicated history of P, P1, and 
Pk, the PX2 antigen was therefore renamed GLOB4 (ISBT 
no. 028004) by the ISBT Working Party.3 For clarification, 
the current terminology of the GLOB blood group system is 
summarized in Table 1.
Another interesting aspect of PX2 concerns host–pathogen 
interaction. Clostridium difficile toxin A is internalized via 
endocytosis after binding to epithelial cells in the large 
intestine. This toxin has been shown to bind to the terminal 
GalNAc of PX2, which is therefore considered the human 
receptor for the toxin.4 Interestingly, sialylation of the same 
epitope inhibits binding and may therefore modulate the toxic 
effects of C. difficile.5
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Fig. 1 Schematic summary of PX2 antigen synthesis and its 
precursor molecule paragloboside. The α- or β-linkages are shown 
along with the informative numbers in the 1,3 or 1,4 glycosidic 
bonds.
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Traditionally, p phenotype blood units (i.e., those lacking 
P, P1, and Pk antigens) have often been used to manage the 
transfusion needs of patients with the rare Pk phenotype. The 
reasoning behind this has simply been a matter of availability. 
Though the clinical significance of anti-PX2 is not yet fully 
understood, this may no longer be the most favorable option 
for Pk patients — because of elevated levels of PX2 on the p 
phenotype. Thus, a recommendation to avoid transfusing p 
phenotype units for Pk patients has been made.
Next-generation sequencing data from the 1000 Genomes 
Project has been extracted for all 36 blood group systems, 
correlated with known variants and visualized in a custom-
designed database, www.erythrogene.com, by Möller et al.6 
Bioinformatic analysis of the B3GALNT1 locus revealed it to 
be highly conserved, although an allele with the c.376G>A 
mutation was found in 5.2 percent of the population worldwide. 
This allele, shown to be associated with normal expression of P,7 
was named GLOB*02. Subsequently, the c.598delT mutation 
linked to c.376G>A8 was therefore renamed GLOB*02N.01 
(and GLOB*01N.10 was retired).
Also, another nonsense mutation at the B3GALNT1 locus, 
abolishing P synthase activity, has been identified and added 
to the 12 alleles already recognized by ISBT. The substitution 
c.420T>G introduces a premature stop codon, p.Tyr140Ter, 
and was given the allele name GLOB*01N.13.9 The complete 
list of GLOB alleles is available at http://www.isbtweb.org/
working-parties/red-cell-immunogenetics-and-blood-group-
terminology/.
Update on the GLOB Collection
The high-prevalence antigen Luke (LKE) was removed 
from the GLOB collection (209003) to the 901 series and 
assigned the ISBT number 901017.3 Hence, the GLOB 
collection has been rendered obsolete.
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Table 1. The GLOB blood group system
Antigen ISBT system no. ISBT antigen ISBT antigen no.
P GLOB 028 GLOB1 028001
PX2 GLOB 028  GLOB4* 028004
Note that the GLOB system remains but the GLOB collection has been 
retired and hence 209001, 209002, 209003, and 209004 are obsolete 
(previously used for P, Pk, LKE, and PX2, respectively).
*Previously known as GLOB2 but after the ISBT congress in Toronto in June 
2018, GLOB2 and GLOB3 were made obsolete.3
ISBT = International Society of Blood Transfusion; no. = number.
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